CEVR analyzes the value of strategies to improve health and health care.

About Us

News & Events

New CEVR publication: Variation in Medicaid and commercial payer coverage of aducanumab for Alzheimer's disease

Introduction Ever since the United States Food and Drug Administration (FDA) approved aducanumab and Centers for Medicare & Medicaid Service (CMS)...

Read more February 28, 2023
New CEVR publication: Examining US commercial health plans’ use of The Institute for Clinical and Economic Review’s reports in specialty drug coverage decisions

ABSTRACT Background The Institute for Clinical and Economic Review (ICER) has emerged in a visible role in US health care. However, it is unclear to ...

Read more February 27, 2023
What are the Top Questions the CEA Registry Helped Answer in 2022?

The Biggest Research Questions the CEA Registry Helped Answer in 2022 We compiled our favorite publications from 2022 that were supported by data from...

Read more February 3, 2023
View All News & Events

Recent Publications

Alzheimer's & Dementia
Variation in Medicaid and commercial payer coverage of aducanumab for Alzheimer's disease
View publication
February 28, 2023
Journal of Managed Care & Specialty Pharmacy
Examining US commercial health plans’ use of The Institute for Clinical and Economic Review’s reports in specialty drug coverage decisions
View publication
February 27, 2023
Health Affairs Forefront
Options for CMS drug price negotiations
View publication
January 4, 2023
Patient Preference and Adherence
Patient and caregiver views on measures of the value of health interventions
View publication
December 20, 2022
Value in Health
The impact on cost-effectiveness of accounting for generic drug pricing: Four case studies
View publication
November 3, 2022
Applied Health Economics and Health Policy
Family spillover effects: Are economic evaluations misrepresenting the value of healthcare interventions to society?
View publication
August 23, 2022
Journal of Managed Care & Specialty Pharmacy
When are breakthrough therapies cost-effective?
View publication
July 28, 2022
JAMA Network Open
Racial and ethnic differences in hospice use and hospitalizations at end-of-life among Medicare beneficiaries with dementia
View publication
June 9, 2022
Medical Decision Making
Trends in author-reported cost-effectiveness thresholds in the United States from 1995 to 2018: Implications for discount rates
View publication
May 7, 2022
The American Journal of Managed Care
Patients’ access to 2018 FDA-approved drugs 1 year post approval
View publication
April 12, 2022
PharmacoEconomics
Addressing challenges to alternative payment models for new Alzheimer’s disease therapies for US commercial payers
View publication
May 13, 2022
View All Publications

The CEVR Team

Our team of experienced, dedicated researchers is led by health economists Peter Neumann and Josh Cohen. Together we produce cutting-edge health care cost-effectiveness research.

Meet the CEVR Team

Our Databases

Our comprehensive databases provide the information individuals and organizations need to analyze the benefits, risks, and costs of strategies to improve health and health care.

CEA Registry

The CEA Registry is a comprehensive database of 9,080 cost-utility analyses on a wide variety of diseases and treatments.

View Registry

Global Health CEA Registry

The GH CEA Registry is the first comprehensive database to compile articles utilizing the “cost-per-DALY averted” metric to measure the efficacy of health interventions.

View Registry

SPEC Database

The Specialty Drug Evidence and Coverage (SPEC) Database is a new data resource developed with the goal of providing an empirical basis to commercial payer specialty drug coverage.

View Database
Learn About Our Databases